Introducing Inhalytix™: a new solution for analysing and managing inhaler test data from Copley

Inhalytix™ is a completely new software solution from Copley, the global leader in inhaler testing equipment, that brings a standardized approach to cascade impactor data analysis, efficiently converting raw data into performance-defining metrics for all inhaled products.

Cascade impactors determine aerodynamic particle size distribution (APSD), a critical quality attribute for inhaled drug delivery. Inhalytix™ is flexible, user-configurable, and suitable for all cascade impactors in routine use, for both standard and bespoke test set-ups and methods. It handles the entry, analysis, and reporting of APSD data to the company and regulatory standards, in accordance with draft USP Chapter <1603>, Ph. Eur. Chapter 2.9.18 and relevant US FDA guidance. The software also serves as a database for laboratory cascade impactor inventory enhancing data traceability and integrity.

Cascade impaction involves the quantitative recovery and chemical analysis (typically by HPLC) of the size-fractionated aerosol from an inhaled product to generate a drug-specific APSD. The technique generates substantial quantities of data. Inhalytix™ is the successor to Copley’s highly regarded CITDAS™ software, built from the ground up, drawing on the company’s established expertise in this area. It uses the same core calculation protocols but offers significantly enhanced functionality allowing customers to configure:

  • Reports – choosing which metrics to include to ensure the consistent and informative delivery of results, to meet regulatory requirements.
  • Equipment – selecting from a library of test equipment to handle standard and complex equipment configurations.
  • Methods – to combine detailed product information with reporting and equipment configurations, and to define metrics such as stage groupings and fine particle dose.

Interactive routine analysis, with a defined method, proceeds via a simple three-step process: Prepare, Execute and Analyse. Data can be entered manually or imported and comparison tools simplify the assessment of the results, especially when comparing test and reference products in the case of generics.

Using the equipment database users can link mensuration data, which quantifies changes in the critical dimensions of an in-use impactor, to specific, serialized impactors. This capability enhances data traceability and makes it possible to use actual rather than nominal dimensions to calculate APSDs, with greater accuracy.

Inhalytix™ incorporates new metrics such as Impactor Sized Mass (ISM), Large Particle Mass (LPM), Small Particle Mass (SPM), and LPM/SPM ratio, amongst others and handles a broad array of impactors and components, including abbreviated impactors such as the Fast Screening Andersen (FSA). The software is 21 CFR Part 11 compliant with user access management and audit trails and is also fully validated with a unique, built-in, auto-validation capability. Available in various expandable, multi-user license configurations, Inhalytix™ can be either server, cloud, or individual computer-based, enabling access in and away from the lab.

Find out more about the capabilities of Inhalytix™ Here

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Copley Scientific Limited. (2021, March 22). Introducing Inhalytix™: a new solution for analysing and managing inhaler test data from Copley. News-Medical. Retrieved on August 02, 2021 from https://www.news-medical.net/news/20210322/Introducing-Inhalytixe284a2-a-new-solution-for-analysing-and-managing-inhaler-test-data-from-Copley.aspx.

  • MLA

    Copley Scientific Limited. "Introducing Inhalytix™: a new solution for analysing and managing inhaler test data from Copley". News-Medical. 02 August 2021. <https://www.news-medical.net/news/20210322/Introducing-Inhalytixe284a2-a-new-solution-for-analysing-and-managing-inhaler-test-data-from-Copley.aspx>.

  • Chicago

    Copley Scientific Limited. "Introducing Inhalytix™: a new solution for analysing and managing inhaler test data from Copley". News-Medical. https://www.news-medical.net/news/20210322/Introducing-Inhalytixe284a2-a-new-solution-for-analysing-and-managing-inhaler-test-data-from-Copley.aspx. (accessed August 02, 2021).

  • Harvard

    Copley Scientific Limited. 2021. Introducing Inhalytix™: a new solution for analysing and managing inhaler test data from Copley. News-Medical, viewed 02 August 2021, https://www.news-medical.net/news/20210322/Introducing-Inhalytixe284a2-a-new-solution-for-analysing-and-managing-inhaler-test-data-from-Copley.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.